Peer-reviewed veterinary case report
COX enzyme levels and cancer survival in dogs and cats
By Gregório, Hugo et al.·Published in Veterinary medicine and science·2021·AniCura ®·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.
- Species:
- dog
Plain-English summary
A review of studies found that certain proteins called COX-1 and COX-2 can help predict how well dogs and cats with cancer might do. Specifically, COX-2 is linked to worse outcomes in various types of tumors, including mammary tumors and mast cell tumors in dogs, while COX-1 is associated with poor prognosis in feline oral squamous cell carcinoma. This information can help veterinarians understand the severity of cancer in pets and guide treatment decisions. Overall, the findings suggest that monitoring COX-2 levels in dogs and COX-1 levels in cats could be important for assessing cancer prognosis.
People also search for: dog cancer prognosis · feline oral squamous cell carcinoma treatment · COX-2 in dog tumors
Abstract
Cyclooxygenase (COX) isoforms-1 and -2 have been extensively investigated in cancer. Although COX-2 is the isoform most studied and has been described in several malignancies associated with histologic criteria of malignancy and worse prognosis, COX-1 has also been linked to some forms of cancer. With the present review our aim was to summarize the current state of knowledge and clarify if and in which type of tumours COX-1 and/or COX-2 expression have real prognostic implications. We searched PubMed database for prognostic studies using predefined inclusion criteria in order to ascertain the prognostic value of COX-1 and COX-2 in malignant neoplasia in dogs and cats. Eighteen studies were analysed. COX-2 was shown to be a negative prognostic factor in canine and feline mammary tumours, canine mast cell tumour, canine melanoma, canine osteosarcoma and canine renal cell carcinoma. COX-1 showed a negative prognostic value in feline oral squamous cell carcinoma (SCC). We found high heterogeneity among studies regarding COX immunohistochemical evaluation methodology even in the same type of neoplasia pointing out the need for its standardization at least by tumour type. The available data support the use of COX-2 as a prognostic factor in canine (mammary carcinoma, mast cell tumour, melanoma, osteosarcoma and renal carcinoma) and feline (mammary carcinoma) cancers. For COX-1, its use is advised in feline oral SCC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33751829/